VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ICML 2019 | E4412 update: ipi-nivo-brentuximab for R/R Hodgkin lymphoma

Catherine Diefenbach, MD, NYU Langone, New York, NY, gives an update on the extended follow-up of the E4412 trial (NCT01896999), which investigated the combination of ipilimumab, nivolumab and brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter